A prospective, longitudinal cohort study to assess the humoral and cellular immune response and adverse events post COVID-19 vaccination in Primary Sjögren'S Syndrome patients compared to healthy controls
Latest Information Update: 29 Jun 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 29 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism